Karyopharm Research Development from 2010 to 2024

KPTI Stock  USD 1.06  0.03  2.75%   
Karyopharm Therapeutics' Research Development is increasing with slightly volatile movements from year to year. Research Development is predicted to flatten to about 108.8 M. For the period between 2010 and 2024, Karyopharm Therapeutics, Research Development quarterly trend regression had mean deviation of  47,240,115 and range of 152.7 M. View All Fundamentals
 
Research Development  
First Reported
2011-12-31
Previous Quarter
35.6 M
Current Value
39.3 M
Quarterly Volatility
12.5 M
 
Yuan Drop
 
Covid
Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm main balance sheet or income statement drivers, such as Depreciation And Amortization of 503.5 K, Interest Expense of 25 M or Selling General Administrative of 67.5 M, as well as many exotic indicators such as Price To Sales Ratio of 0.64, Dividend Yield of 0.0 or Days Sales Outstanding of 52.74. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
This module can also supplement Karyopharm Therapeutics' financial leverage analysis and stock options assessment as well as various Karyopharm Therapeutics Technical models . Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Latest Karyopharm Therapeutics' Research Development Growth Pattern

Below is the plot of the Research Development of Karyopharm Therapeutics over the last few years. It is Karyopharm Therapeutics' Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Karyopharm Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
   Research Development   
       Timeline  

Karyopharm Research Development Regression Statistics

Arithmetic Mean93,526,477
Geometric Mean65,492,584
Coefficient Of Variation60.51
Mean Deviation47,240,115
Median107,273,000
Standard Deviation56,595,806
Sample Variance3203.1T
Range152.7M
R-Value0.87
Mean Square Error848.9T
R-Squared0.75
Significance0.000027
Slope10,988,258
Total Sum of Squares44843.2T

Karyopharm Research Development History

2024108.8 M
2023138.2 M
2022148.7 M
2021160.8 M
2020150.8 M
2019122.3 M
2018161.4 M

About Karyopharm Therapeutics Financial Statements

There are typically three primary documents that fall into the category of financial statements. These documents include Karyopharm Therapeutics income statement, its balance sheet, and the statement of cash flows. Karyopharm Therapeutics investors use historical funamental indicators, such as Karyopharm Therapeutics's Research Development, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics investors may use each financial statement separately, they are all related. The changes in Karyopharm Therapeutics's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Karyopharm Therapeutics's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Karyopharm Therapeutics Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Karyopharm Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Research Development138.2 M108.8 M
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Karyopharm Therapeutics in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Karyopharm Therapeutics' short interest history, or implied volatility extrapolated from Karyopharm Therapeutics options trading.

Building efficient market-beating portfolios requires time, education, and a lot of computing power!

The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.

Try AI Portfolio Architect
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Portfolio Optimization module to compute new portfolio that will generate highest expected return given your specified tolerance for risk.

Complementary Tools for Karyopharm Stock analysis

When running Karyopharm Therapeutics' price analysis, check to measure Karyopharm Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Karyopharm Therapeutics is operating at the current time. Most of Karyopharm Therapeutics' value examination focuses on studying past and present price action to predict the probability of Karyopharm Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Karyopharm Therapeutics' price. Additionally, you may evaluate how the addition of Karyopharm Therapeutics to your portfolios can decrease your overall portfolio volatility.
Fundamentals Comparison
Compare fundamentals across multiple equities to find investing opportunities
CEOs Directory
Screen CEOs from public companies around the world
Money Managers
Screen money managers from public funds and ETFs managed around the world
Earnings Calls
Check upcoming earnings announcements updated hourly across public exchanges
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Pair Correlation
Compare performance and examine fundamental relationship between any two equity instruments
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
Performance Analysis
Check effects of mean-variance optimization against your current asset allocation
Cryptocurrency Center
Build and monitor diversified portfolio of extremely risky digital assets and cryptocurrency
Is Karyopharm Therapeutics' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Karyopharm Therapeutics. If investors know Karyopharm will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(1.25)
Revenue Per Share
1.279
Quarterly Revenue Growth
0.005
Return On Assets
(0.27)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Karyopharm Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Karyopharm Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Karyopharm Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.